Preliminary investigations provide indications of the therapeutic benefits of GLP‐1 receptor agonists for people with dementia, eating disorders, psychopharmacologically induced weight gain, depression, anxiety and substance use disorders. The gene discussed is GLP1R; the disease is major depressive disorder.